Back to Search
Start Over
Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal center.
- Source :
- NPJ Vaccines; 1/25/2021, Vol. 6 Issue 1, p1-10, 10p
- Publication Year :
- 2021
-
Abstract
- The RV144 HIV-1 vaccine trial has been the only clinical trial to date that has shown any degree of efficacy and associated with the presence of vaccine-elicited HIV-1 envelope-specific binding antibody and CD4+ T-cell responses. This trial also showed that a vector-prime protein boost combined vaccine strategy was better than when used alone. Here we have studied three different priming vectors—plasmid DNA, recombinant MVA, and recombinant VSV, all encoding clade C transmitted/founder Env 1086 C gp140, for priming three groups of six non-human primates each, followed by a protein boost with adjuvanted 1086 C gp120 protein. Our data showed that MVA-priming favors the development of higher antibody binding titers and neutralizing activity compared with other vectors. Analyses of the draining lymph nodes revealed that MVA-prime induced increased germinal center reactivity characterized by higher frequencies of germinal center (PNA<superscript>hi</superscript>) B cells, higher frequencies of antigen-specific B-cell responses as well as an increased frequency of the highly differentiated (ICOS<superscript>hi</superscript>CD150<superscript>lo</superscript>) Tfh-cell subset. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 20590105
- Volume :
- 6
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- NPJ Vaccines
- Publication Type :
- Academic Journal
- Accession number :
- 148341357
- Full Text :
- https://doi.org/10.1038/s41541-020-00277-1